American Society of Hematology

11/14/2025

📣Deadline extended! Apply for the ASH Careers in Hematology Advancement Mentorship Program — a year-long opportunity to be paired with an expert mentor in classical hematology.

This is a terrific opportunity for fellows pursuing clinical careers to access mentorship resources beyond their institution 🩺

🧭 Mentors, there is still time for you to apply too! Shape the future of hematology.

🗓️ Submit your application by November 20: https://ow.ly/wg8h50Xr7EH

11/12/2025

A day at the beach changed everything for Michael. A bodysurfing accident in 2011 led to a fractured neck and an unexpected discovery: multiple myeloma, even though he had no symptoms. Thanks to treatment, including an autologous stem cell transplant, Michael is now in remission.

Now, Michael channels his experience into advocacy, urging continued federal support for blood cancer research. Without it, future breakthroughs, including advances in CAR T-cell therapies, could be at risk.

Raise your voice for research: https://ow.ly/959s50XqFlW

11/11/2025

🩸🌏 Highlights of ASH is traveling the globe to help you incorporate breakthroughs from the 67th ASH Annual Meeting and Exposition ( ) into your practice.

Here are three reasons to attend:

1️⃣ Maximize your time. Get the most essential updates in just two days.

2️⃣ Make meaningful connections. Engage with experts and peers in a small-meeting environment optimal for interaction.

3️⃣ Get regionally relevant insights you take back to your patients. Speakers tailor their presentations to your local practice needs.

Register early and save: https://ow.ly/3uXw50XpJ29

11/11/2025

Preserving human hematopoietic stem cell (HSC) function early in culture can maximize the yield of functional cells for each patient.

Learn more about the study, published in Blood, by joining the authors for the next ASH journal club!

What you’ll learn:

🌟The key molecular and functional changes that occur when HSCs are cultured outside the body for clinical approaches (ex vivo).

🌟How early intervention approaches, such as JAK/STAT inhibition through ruxolitinib, can preserve HSC function ex vivo.

🌟How to recognize the challenges of scalability and cost in personalized ex vivo gene therapy approaches, and how optimizing HSC biology ex vivo can help overcome them.

📌Register now: https://ow.ly/273C50Xolje

11/10/2025

is your front-row seat to the latest in hematology, showcasing breakthroughs and innovations shaping the future of research and the care of patients.

One of this year’s hottest topics is AI. Join the joint session Advancing Hematology Through Artificial Intelligence to learn about the impact of on science, diagnostics, and clinical care, whether you are a clinical researcher, providing care of patients, or conducting other types of scientific research.

Register today: https://ow.ly/QoQA50XpIjv

11/10/2025

The official app is here!

Access the full program, abstracts, and other features for seamless navigation and engagement — all in the palm of your hand.

📌Three ways to access

iOS: ‎ https://ow.ly/nRXy50XpvtU

Android: https://ow.ly/riKZ50XpvtT

🌟New! Web app (no download required) https://ow.ly/oRRX50XpvtP

11/08/2025

Become your institution’s quality improvement MVP!

The ASH Quality Improvement Training Institute (QITI) is a no-cost, 16-month quality improvement program that combines specialized hematology training with personalized coaching to guide your team’s project from concept to implementation.

🎥 Members of the first QITI cohort learned to lead multidisciplinary QI teams for lasting impact on patient care.

Learn more and apply by January 5: https://ow.ly/qQfB50Xov6C

11/07/2025

11/07/2025

Are you prepared to recognize and mitigate toxicities following CAR T-cell and other immune effector-cell therapies?

Join leading experts Drs. Nancy Berliner and Nirali Shah and moderator Dr. Kim Nichols for updates on our current understanding of hemophagocytic lymphohistiocytosis (HLH) and cytokine release syndrome (CRS), including a review of treatment options and evolution in our understanding of their pathophysiology.

Explore🔎

📌The evolution in immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) as a key toxicity

📌Updates in diagnostic and treatment approaches to IEC-HS

📌The difference between primary/pediatric HLH and secondary/adult HLH

📌The triggers of secondary HLH

📌How the nature of the trigger of HLH impacts choice of therapy

Enroll today! https://ow.ly/wVLv50XomcO

11/06/2025

ASH is proud to join 455 organizations in urging Congress to provide at least $47.2 billion for the NIH in FY26, in addition to funding for ARPA-H.

NIH-funded research is essential to advancing hematology—from developing gene therapies to improving treatments for sickle cell disease and blood cancers. Sustained investment supports innovation, strengthens the research workforce, and delivers hope to patients nationwide.

ASH calls on Congress to finalize FY26 appropriations that prioritize medical research and protect the future of scientific discovery.

Read the full letter below and let’s continue the ! https://ow.ly/Swx350Xm47j

11/06/2025

Registrations are now open for Highlights of ASH in Asia-Pacific!

Join leading hematology experts in Kuala Lumpur, Malaysia and explore groundbreaking research from the latest ASH Annual Meeting.

Discover the most influential studies, engage with global thought leaders, and learn how to apply the latest advances directly to your practice.

🗓️April 10-11, 2026
👉 Register now: https://ow.ly/VUYS50XmBw7

Malaysian Society of Haematology

11/05/2025

¡Inscripciones abiertas para el 2026 Highlights of ASH® in Latin America!

Participe en el evento que reúne a expertos internacionales y ofrece un resumen del ASH Annual Meeting, el congreso mundial más importante de hematología.

Temas del programa (hematología clásica y maligna):

🧬 Leucemias: LLA, LMA, LMC
🩸 Linfomas: agresivos, indolentes, de células del manto, cutáneos y T periféricas
⚠️ Trastornos y síndromes: mieloma múltiple, hemoglobinopatías, trastornos de los glóbulos rojos, trastornos hemorrágicos, falla medular, SMD, MAT, HPN
💊 Tratamientos y terapias: CAR-T, trasplantes, inmunoterapias y terapias dirigidas
🌍 Otros temas: neoplasias mieloproliferativas, tromboembolismo venoso, hemólisis y vías del complemento

💡 Los asociados de sociedades afiliadas a la ASH cuentan con condiciones especiales de inscripción. Consulte el sitio oficial y comuníquese con su sociedad para hacer posible su participación.

🔗 ¡Inscríbase ahora! https://ow.ly/oet250XlLT6